What is the MDQ assessment tool?

The Mood Disorder Questionnaire (MDQ) was developed by a team of psychiatrists, researchers and consumer advocates to address the need for timely and accurate evaluation of bipolar disorder. n The MDQ is a brief self-report instrument that takes about 5 minutes to complete.

Who can administer the MDQ?

The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient. The MDQ consists of 15 questions and takes about 5 minutes to complete.

Is the MDQ reliable?

Results: The long-term reliability of the MDQ was limited as the correct recall of individual items ranged from 44.6% to 68.8% after two years.

What is the MDQ used for?

The Mood Disorder Questionnaire (MDQ) was developed by a group of psychiatrists, researchers and patient advocates. It is simple and involves reporting against 15 items. It is a screening instrument for the detection of bipolar disorder (BPD).

What are the results of the MDQ validation study?

The validation study administered the MDQ to patients at five psychiatric clinics in the United States (Hirschfeld, 2000). The results were used to determine cut off points for items, specificity, and sensitivity.

Is the Mood Disorder Questionnaire ( MDQ ) a diagnostic tool?

The Mood Disorder Questionnaire (MDQ) Scoring Algorithm POSITIVE SCREEN All three of the following criteria must be met: Scoring: This instrument is designed for screening purposes only and is not to be used as a diagnostic tool. *Derived from Hirschfeld RM. Am J Psychiatry. 2000:157(11):1873-5.

How many questions are there on the MDQ?

The MDQ consists of 15 questions divided in two parts. Part I contains 13 questions that refer to most common bipolar disorder symptoms whilst part II questions refer to family history of mental disease, past personal diagnoses and to perceived disease severity. The questionnaire is straightforward and takes about 5 minutes to administer.

Is the MDQ a good tool for diagnosing BD?

In sum, the MDQ is a useful screening tool for BD, demonstrating validity in clinical settings and across cultures. However, consideration should be given towards its higher sensitivity to detect BD type 1 compared to other BD on the spectrum, and its low sensitivity in general populations.